Monoclonal antibodies in chronic lymphocytic leukemia.

Abstract

Multiple options are now available for the treatment of chronic lymphocytic leukemia. Over the last 10 years, monoclonal antibodies have become an integral part of the management of this disease. Alemtuzumab has received approval for use in patients with fludarabine-refractory chronic lymphocytic leukemia. Rituximab has been investigated extensively in chronic lymphocytic leukemia both as a single agent and in combination with chemotherapy and other monoclonal antibodies. Epratuzumab and lumiliximab are newer monoclonal antibodies in the early phase of clinical development. This article will review the monoclonal antibodies more commonly used to treat chronic lymphocytic leukemia, the results obtained with monoclonal antibodies as single agents and in combination with chemotherapy, and other biological agents and newer compounds undergoing clinical trials.

• Authors: Alessandra Ferrajoli, Stefan Faderl, Michael J Keating
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 6 Issue 9 Pg. 1231-8 (Sep 2006) ISSN: 1744-8328 [Electronic] England
• PMID: 17020457 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents

Topics

• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, immunology, therapy)